Vitamin D supplementation improves Long COVID: a randomized, double-blind, placebo-controlled trial

Vitamin D supplementation improves Long COVID: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400095046

Enrollment

Unknown

Registered

2024-12-31

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

test group:Vitamin D supplements

Control group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meeting the definition of "Long COVID". 2. 18 years of age or older. 3. Local residence in Chongqing for more than six months.

Exclusion criteria

Exclusion criteria: 1. Long-term use of vitamin D3, calcitonin, calcium or diuretics, digitalis, phosphorus-containing drugs. 2. Patients with hypercalcemia or vitamin D hyperplasia or hyperphosphatemia with nephrogenic rickets. 3. Presence of serious underlying diseases: tumors, strokes, organ failure, etc.. 4. Allergic to gelatin and glycerin.

Design outcomes

Primary

Measure	Time frame
Elimination of fatigue;	—

Secondary

Measure	Time frame
Serum levels of vitamin D;Adverse reaction rate;Changes in other symptoms of Long COVID;	—

Countries

China

Contacts

Public ContactXiangyu Ma

Army Medical University

xymacq@hotmail.com+86 138 8345 5707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026